Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck stock looks fairly valued as Keytruda risks, slower EPS growth, and debt weigh on upside. Click here to read an ...

Merck & Co., Inc. (NYSE:MRK) has surged over 38% in 2026 so far, outperforming the broader market. Merck is no longer being ...

Shares of Moderna Inc. and Merck & Co. fell after reports emerged about the results of the companies’ widely anticipated ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health ...

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...

Germany’s Merck KGaA has agreed to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion ...

Merck KGaA agreed to acquire Silence Therapeutics Plc for about $1.1 billion in a cash transaction as the German science ...

Merck & Co., Inc. is currently listed on NYSE under MRK. One share of MRK stock can currently be purchased for approximately $145.60. Is Merck & Co., Inc. listed on the NASDAQ or NYSE? Merck & Co., ...

Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer ...

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight ...